U. Oz, Suna Sibel Rizvanoğlu, Emrah Şefik Abamor, Göhkan Cengi̇z, Hale Berber, Serap Derman, Müjde Eryilmaz, Asuman Bozkir
{"title":"AMFOTERİSİN-B ENKAPSÜLE EDİLMİŞ NANOPARTİKÜLLERİN ANTİMİKROBİYAL POTENSİNİN DEĞERLENDİRİLMESİ İÇİN FARMAKOPE YÖNTEMİNİN UYGULANMASI","authors":"U. Oz, Suna Sibel Rizvanoğlu, Emrah Şefik Abamor, Göhkan Cengi̇z, Hale Berber, Serap Derman, Müjde Eryilmaz, Asuman Bozkir","doi":"10.33483/jfpau.1352203","DOIUrl":null,"url":null,"abstract":"Objective: The aim of this study is the development of Amphotericin B loaded polymeric nanoparticles and the determination of the potency of Amphotericin B nanoformulation samples and commercially supplied Amphotericin B samples in comparison with reference Amphotericin B standard, according to the protocol detailed in the United States Pharmacopoeia.\nMaterial and Method: Amphotericin B nanoparticles were fabricated using single emulsion method. The comparison of the potencies of the AmB nanoformulation and commercial Amphotericin B with the antimicrobial potency of the reference Amphotericin B standard was performed using the disk diffusion method specified in the United States Pharmacopeia.\nResult and Discussion: Amphotericin B loaded poly(ethylene glycol)-b-poly(ɛ-caprolactone) nanoparticles successfully developed having the average hydrodynamic diameter of 215.14±0.72 nm and PDI value of 0.18±0.02. The Amphotericin B encapsulation efficiency, which was determined using an HPLC method, was 66.4±1.42%. The % potency of commercial Amphotericin B was calculated as 95.7%, while the % potency of the nanoformulation of Amphotericin B was calculated as 99.1%, indicating the favor of utilizing polymeric nanoparticles as delivery systems.","PeriodicalId":7891,"journal":{"name":"Ankara Universitesi Eczacilik Fakultesi Dergisi","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ankara Universitesi Eczacilik Fakultesi Dergisi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.33483/jfpau.1352203","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The aim of this study is the development of Amphotericin B loaded polymeric nanoparticles and the determination of the potency of Amphotericin B nanoformulation samples and commercially supplied Amphotericin B samples in comparison with reference Amphotericin B standard, according to the protocol detailed in the United States Pharmacopoeia.
Material and Method: Amphotericin B nanoparticles were fabricated using single emulsion method. The comparison of the potencies of the AmB nanoformulation and commercial Amphotericin B with the antimicrobial potency of the reference Amphotericin B standard was performed using the disk diffusion method specified in the United States Pharmacopeia.
Result and Discussion: Amphotericin B loaded poly(ethylene glycol)-b-poly(ɛ-caprolactone) nanoparticles successfully developed having the average hydrodynamic diameter of 215.14±0.72 nm and PDI value of 0.18±0.02. The Amphotericin B encapsulation efficiency, which was determined using an HPLC method, was 66.4±1.42%. The % potency of commercial Amphotericin B was calculated as 95.7%, while the % potency of the nanoformulation of Amphotericin B was calculated as 99.1%, indicating the favor of utilizing polymeric nanoparticles as delivery systems.